Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor by Bayó-Puxan, Núria et al.
Combined Use of Oligopeptides, Fragment Libraries, and
Natural Compounds: A Comprehensive Approach To
Sample the Druggability of Vascular Endothelial Growth
Factor
Nﬄria Bay-Puxan,[a] Ricard Rodrguez-Mias,[a] Michael Goldflam,[a] Martin Kotev,[a]
Sonia Ciudad,[a] Christopher J. Hipolito,[b] Monica Varese,[a] Hiroaki Suga,[b] Ramn Campos-
Olivas,[c] Xavier Barril,[d, e, f] Vctor Guallar,[f, g] Meritxell Teixid,[a] Jesﬄs Garca,[a] and
Ernest Giralt*[a, h]
Introduction
Protein–protein interactions
Proper cellular behavior is governed by a large map of interac-
tions between various protein partners, the so-called interac-
tome.[1] Research into protein–protein interactions (PPIs) has
emerged as an important and challenging field in chemical
biology and medicinal chemistry.[2] New and classical screening
approaches in combination with medicinal chemistry have
brought more than 12 small-molecule PPI modulators into clin-
ical development, and it is expected that the market for this
class of compounds will reach 600 million EUR in the next five
years.[3] However, the design of molecules that interfere with
these interactions is hindered by the size and topology of pro-
tein–protein interfaces. The surface of many proteins has
evolved to interact either with other proteins or with small
molecules. The contact area in a protein–protein interface is
considerably larger (1500–3000 2) than the average contact
surface in the interaction between proteins and small mole-
cules (300–1000 2).[4] In addition, protein–protein interfaces
tend to be flat and often lack the grooves or cavities[4] normal-
ly present in protein surfaces involved in the binding of small
molecules. These considerations led to the concept of protein
“druggability” coined by Hopkins and Groom.[5] Despite the
large size of protein–protein interfaces, early studies revealed
that not all interfacial residues contribute equally to complex
stability.[6] A small subset of critical residues, called hot spots,[7]
are responsible for a large fraction of the binding free energy.
It has also been pointed out that large PPIs are often dominat-
The modulation of protein–protein interactions (PPIs) is emerg-
ing as a highly promising tool to fight diseases. However,
whereas an increasing number of compounds are able to dis-
rupt peptide-mediated PPIs efficiently, the inhibition of
domain–domain PPIs appears to be much more challenging.
Herein, we report our results related to the interaction be-
tween vascular endothelial growth factor (VEGF) and its recep-
tor (VEGFR). The VEGF–VEGFR interaction is a typical domain–
domain PPI that is highly relevant for the treatment of cancer
and some retinopathies. Our final goal was to identify ligands
able to bind VEGF at the region used by the growth factor to
interact with its receptor. We undertook an extensive study,
combining a variety of experimental approaches, including
NMR-spectroscopy-based screening of small organic fragments,
peptide libraries, and medicinal plant extracts. The key feature
of the successful ligands that emerged from this study was
their capacity to expose hydrophobic functional groups able
to interact with the hydrophobic hot spots at the interacting
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ed by hot segments, which are continuous peptide stretches
that contribute the most to the binding interaction energy.[8]
These observations have important implications for the devel-
opment of small-molecule inhibitors of PPIs. These interactions
have been traditionally considered as targets with low drugga-
bility potential. However, targeting hot spots or predominant
hot segments makes it potentially feasible to disrupt PPIs by
means of small- or medium-sized molecules.
VEGF–VEGFR: a therapeutically relevant protein–protein
interaction system
Vascular endothelial growth factor (VEGF or VEGF-A) is proba-
bly the most important soluble factor involved in tumor angio-
genesis.[9, 10] VEGF belongs to the PDFG supergene family,
which in mammals also includes VEGF-B, -C, -D, and -E, with
which the former shares a varying degree of homology. VEGF
is a glycoprotein expressed in various spliced isoforms ranging
from 121 to 206 residues in length, and its 165-amino acid iso-
form is the most abundant. All these isoforms share a common
homodimeric N-terminal receptor binding domain that has the
ability to bind three tyrosine kinase receptors, namely, VEGFR-
1 (also known as Flt-1), VEGFR-2, and VEGFR-3.[11] VEGF mono-
mers are arranged in an antiparallel manner and are covalently
linked by two symmetrical intermonomer disulfide bridges be-
tween Cys51 and Cys60. The monomer structure is character-
ized by a four-stranded central b sheet (i.e. , strands b1, b3, b5,
and b6) that is stabilized by a cystine knot motif formed by
three intramolecular disulfide bonds (i.e. , Cys26Cys68, Cys57
Cys102, and Cys61Cys104) at one end and by a small hydro-
phobic core at the opposite end. The structure also contains
three additional short b strands (i.e. , b2, b4, and b7) and two
a-helical segments (i.e. , a1 and a2).[12] Two symmetric receptor
binding surfaces at the poles of the VEGF homodimer have
been identified by mutational and structural studies.[13] The
crystal structure of the VEGF–VEGFR-1 complex[14] revealed that
no major conformational changes occur on VEGF upon recep-
tor binding and that the intermolecular interaction is mediated
mainly by hydrophobic contacts. Both X-ray[12] and NMR spec-
troscopy studies[15] suggest that the receptor binding region of
VEGF has intrinsic conformational flexibility. Such flexibility
may have important functional implications that allow the pro-
tein to interact with multiple receptors.
VEGF is overexpressed in most tumors and has a direct
effect on sprouting angiogenesis.[16] It also acts as a survival
factor by enhancing the expression of anti-apoptotic factors
such as Bcl-2.[17] In general, VEGF induces receptor dimerization
and activation of its kinase activity through autophosphoryla-
tion, which triggers a series of intracellular signaling pathways;
it also sets off several processes common to other growth fac-
tors, namely, cell migration, survival, and proliferation.[18]
VEGF is particularly interesting as a therapeutic target be-
cause it acts directly on genetically stable endothelial cells
rather than on tumor cells. Therefore, drugs that target VEGF
are less prone to induce mutation selection on tumor cells and
ultimately confer them with drug resistance.[19] VEGF inhibition
suppresses tumor growth in animal models.[20] VEGF has also
been identified as a key target to mitigate the effects of both
wet age-related macular degeneration (AMD) and diabetes
macular edema (DME), which are vision-limiting complications
of aging and diabetes, respectively. DME affects nearly 30% of
diabetes patients, whereas AMD is the main cause of perma-
nent vision loss in the elderly.[21] High concentrations of VEGF
have been correlated with chronic retinal microvascular
damage. To date, 11 drugs that disrupt VEGF signaling have
been approved for the treatment of several cancer types[22]
and diseases related to macular degeneration.[23] Of these,
seven (i.e. , sunitinib,[24,25] sorafenib,[26,27] pazopanib,[28,29] vande-
tabnib,[30] axitinib,[31] regorafenib,[32] and cabozantinib[33]) are
small molecules that inhibit the intracellular tyrosine kinase ac-
tivity of the receptor. Of the remaining four drugs, two are
monoclonal antibodies targeting either circulating VEGF (i.e. ,
bevacizumab[34]) or the soluble extracellular fraction of the
VEGF receptor (i.e. , ramucirumab[35,36]). In addition, a chimeric
fusion protein (i.e. , aflibercept[37]) and an aptamer (i.e. , pegap-
tanib[38]) have been described to block VEGF.
Recently, a small molecule interacting with the VEGFR-1 D2
domain and preventing VEGF binding was reported.[39] In the
present study, we explored the capacity of small molecules to
directly target the VEGF protein. The results of screening pep-
tide and fragment-based libraries and plant extracts are dis-
cussed.
Results
We tackled the discovery of VEGF ligands by using several ex-
perimental approaches, including fragment screening, design
and evaluation of linear and cyclic peptide libraries, and
screening of plant extracts used in traditional Chinese medi-
cine. We focused our methodology on the use of NMR spec-
troscopy, including the implementation of a highly efficient
chemical shift perturbation (CSP) method based on methyl-13C-
Methionine selective labeling of VEGF. Computational chemis-
try was used to assist the screening process and was used to
facilitate interpretation of the results.
Selective methyl-13C-methionine-labeled VEGF for binding
studies
VEGF11109 (from now on VEGF), a construct comprising resi-
dues 11–109 and containing the structured homodimeric N-ter-
minal receptor binding domain, was chosen because its ex-
pression procedure and its backbone assignment have already
been described.[15] By using 1H–15N HSQC NMR spectroscopy
experiments, a uniformly 15N-labeled VEGF sample was used to
confirm both its fold integrity and its capacity to interact with
v107, a peptide that binds with high affinity to the same
region of VEGF that interacts with the VEGF receptor.[40] In the
presence of v107, considerable changes in more than 50% of
the VEGF NH resonances were observed (results not shown).
Receptor-based 1H–15N HSQC experiments provide information
about the most probable localization of ligand–protein interac-
tions, which can be correlated to their biological functional ef-
fects. However, given the dramatic effects of v107 binding in
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the VEGF 1H–15N HSQC spectra, the interpretation of CSPs may
be misleading. Moreover, this method may be expensive and
time consuming for a high-throughput screening strategy. Al-
ternatively, in our screen of potential VEGF binders, we routine-
ly used one-dimensional ligand-observed techniques such as
saturation transfer difference (STD)[41] and WaterLOGSY experi-
ments,[42] T2-relaxation edited experiments,
[43] and 19F NMR
spectroscopy.[44] However, these techniques also have some
limitations. In particular, for complex mixtures, such as plant
extracts, deconvolution of the contribution of each individual
component may be challenging. In addition, NMR spectrosco-
py methods based on the existence of a fast equilibrium be-
tween the bound and free ligands may not be able to detect
strong binders. Therefore, we focused our efforts on designing
a cost-effective and time-efficient screening method that pre-
served the relevant mapping information. One way to achieve
this goal is the NMR observation of specifically labeled side-
chain resonances of the target protein. This approach has the
potential to improve both the sensitivity and spectral resolu-
tion of the NMR spectra. Moreover, as side chains are less
prone to long-range CSP effects, they may be more reliable
than amide signals for the extraction of structural information.
The mode of interaction of VEGF with its receptors[14,45] and
several peptides[40,46, 47] was extensively studied and structurally
characterized. Of the five VEGF methionine residues, two (i.e. ,
Met18 and Met81) participate in the interaction with either
v107 or VEGFR-1 and become deeply buried in the complex in-
terface. Therefore, incorporation of selectively labeled methio-
nine residues may enable the study of the intermolecular inter-
actions of VEGF. The presence of three methionine residues
(i.e. , Met55, Met78, and Met94) outside the interface could pro-
vide extra information about the specificity of the interaction.
The use of methionine as a labeling probe presents several ad-
ditional advantages. Incorporation of commercially available
methyl-13C-methionine into proteins can be easily accom-
plished by using methionine auxotrophic E. coli strains. These
strains are widely used in protein crystallography to solve the
phase problem by using selenomethionine.[48] The labeling pro-
cedure is cost effective as only 80 mg of methyl-13C-methio-
nine (~300 Eg1) per liter of growth media is required. Most
importantly, 13C-labeled methyl groups show high sensitivity
and favorable NMR relaxation properties.[49] The combined use
of methionine isotopic labeling and NMR spectroscopy detec-
tion was previously described for a carboxymethylated
enzyme[50] and for in-cell NMR spectroscopy experiments.[51]
Methyl-13C-Met-labeled VEGF was obtained following the
procedure described for uniformly 15N-labeled VEGF,[52] except
that the methionine auxotrophic E. coli B834 strain was used
and the minimal medium for cell growth was supplemented
with methyl-13C-Methionine. The protein yield was not greatly
affected by the use of auxotrophic cells. Selectively methyl-13C-
Met-labeled VEGF displayed the expected five correlation sig-
nals in the 1H–13C HSQC NMR spectra (Figure 1). The addition
of v107 revealed that, as expected, the most affected signals
corresponded to methyl groups in Met18 and Met81. The larg-
est change was detected on Met18, probably as a result of
considerable contacts with Trp13 of v107 and the effect of its
aromatic ring currents. The remaining methionine residues
(i.e. , Met55, Met78, and Met94) were virtually unaffected by
v107.
Evaluation of linear and cyclic oligopeptides
Oligopeptides can be considered privileged structures to mod-
ulate PPIs given that their chemical structure is identical to
that involved in PPI interfaces. In addition, they are modular
compounds, they cover a large chemical space, and they can
be easily synthesized.
We designed two groups of all-d dipeptides. The first one
was inspired in the retro-enantioversion[53] of peptide v107,
which was dissected into a series of 20 dipeptides (Table 1).
The second group of 6 peptides was composed by combining
a representative set of amino acids, including Ala, Ile, Trp, Glu,
Arg, and Ser (Table 1).
All-d dipeptides were evaluated against VEGF by STD and
WaterLOGSY experiments. However, after extensive exploration
of a series of experimental parameters (e.g. , protein and ligand
concentration, number of scans, saturation time, and satura-
tion frequency), none of the all-d dipeptides seemed to bind
VEGF.
Figure 1. a) Comparison of the 1H–13C HSQC spectra of methyl-13C-Met la-
beled VEGF (250 mm) in the absence (black) and in the presence of 2 equiva-
lents of peptide v107 (red). The (His)6-VEGF fusion protein used in this ex-
periment contains a methionine outside of the VEGF sequence that is en-
coded by the starting codon of the gene expressing the fusion protein. An
asterisk marks the cross signals of the (His)6-VEGF initial Met. b) Expanded
view of the structure of the VEGF–v107 complex (PDB ID: 1KAT). Homodi-
meric VEGF and v107 are shown in gray and blue, respectively. Methionine
residues of VEGF are shown as stick models.
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Under the hypothesis that the intrinsic flexibility of the all-d
dipeptides analyzed may be detrimental for VEGF binding, we
designed two symmetric cyclic hexapeptides containing chem-
ically distinct dipeptide motifs, namely, Trp-Glu and Ile-Arg. A
d-proline was included to facilitate cyclization and to confer
conformational rigidity to the peptide structure. Cyclopeptides
&d-Pro-Trp-Glu-d-Pro-Trp-Glu& and &d-Pro-Ile-Arg-d-Pro-Ile-
Arg& were obtained by means of 9-fluorenylmethoxycarbonyl
(Fmoc)/tBu peptide chemistry on a solid support (see the Sup-
porting Information). The capacity of the cyclic peptides to in-
teract with VEGF was monitored by a combination of STD and
protein-based CSP experiments by using a methyl-13C-Met-la-
beled VEGF sample. Evidence of binding was only observed for
the Trp-Glu-containing cyclic hexapeptide (Figure 2). In the
presence of the Trp-Glu-containing cyclic hexapeptide, selec-
tive CSPs were induced in the two VEGF methionine residues
(i.e. , Met18 and Met81) located in the receptor interface,
whereas the remaining methionine residues were almost unaf-
fected. Titration experiments indicated that the Trp-Glu-con-
taining cyclic hexapeptide binds VEGF in the low-millimolar
range.
These promising results encouraged us to evaluate a massive
library of cyclic peptides to explore a broader range of sequen-
ces and cycle sizes. For this purpose, we used a recently devel-
oped in vitro selection technology referred to as RaPID
(random nonstandard peptide integrated discovery) system.[54]
The RaPID system combines an RNA display method with flexi-
ble in vitro translation (FIT) technology used for the production
of nonstandard peptides.[55,56] With this methodology, specific
sequences of nonstandard peptides can be ribosomally ex-
pressed according to their mRNA templates.[57] The FIT system
has been applied to the synthesis of a wide variety of Xaa-
tRNAs, for which Xaa represents proteinogenic and nonprotei-
nogenic amino acids[58–62] (see the Supporting Information).
The selection on the mRNA display technology was performed
with a mRNA library encoding for peptides from 5 to 15 amino
acids with random sequences and showed enrichment of spe-
cific motifs (see the Supporting Information). The 10 macrocy-
clic peptides with the highest score were synthesized. Five of
them were prepared as fluorescein-labeled compounds
(Table 2). Macrocyclic peptides were synthesized by using
Fmoc/tBu peptide chemistry on a solid support. They were ob-
tained in low yields (<1%), which could be attributed to the
high frequency of bulky 2,2,4,6,7-pentamethyldihydrobenzofur-
an-5-sulfonyl (Pbf)-protected arginine and b-branched amino
acids and to the presence of multiple conformations of the
final macrocycle.
The VEGF binding ability of unlabeled macrocyclic peptides
(i.e. , peptides 1–5, Table 2) was evaluated by fluorescence po-
Table 1. All-d dipeptide library.
Dipeptides based on the
retroenantio version of v107
Ala-, Ile-, Ser-, Glu-, Arg-,
and Trp-containing dipeptides
N term. Dipeptide[a] N term. Dipeptide[a,b]
H-
Ac-
d-Leu-d-Arg d-Trp-d-Met
H-
d-Ala-d-Xaa
d-Arg-d-Glu d-Met-d-Arg d-Ile-d-Xaa
d-Glu-d-Phe d-Arg-d-Ala d-Ser-d-Xaa
d-Glu-d-Trp d-Ala-d-Ile d-Glu-d-Xaa
d-Trp-d-Glu d-Ile-d-Asp d-Arg-d-Xaa
d-Trp-d-Xaa
[a] Amide as C terminus. [b] Xaa=Ala, Ile, Ser, Glu, Arg, and Trp.
Figure 2. a) Chemical structure of the cyclic hexapeptide &d-Pro-Trp-Glu-d-
Pro-Trp-Glu&. b) STD NMR spectrum (T=278 K) of a sample containing 1 mm
cyclic hexapeptide &d-Pro-Trp-Glu-d-Pro-Trp-Glu& and 10 mm VEGF. c) Over-
lay of the 1H–13C HSQC spectra (T=318 K) of methyl-13C-Met-labeled VEGF
(50 mm) in the absence (black) and in the presence of 2.5 mm cyclopeptide
&d-Pro-Trp-Glu-d-Pro-Trp-Glu& (red). The cross signals of Met78 are folded.
Resonances corresponding to 13C natural abundance peptide are marked by
an asterisk.
Table 2. Macrocyclic peptides designed from the mRNA display technolo-
gy.
Peptide Sequence[a] Purity [%]
1 fPKYRILYVRRRKPCGS >95
2 fRYYIVLKRRRTRISCGS >95
3 FRRYRCYKVYTFTVKC*GS >95
4 FRCRRRIKISYYYLAC*GS >95
5 wRR(Me)FC(Me)S(Me)(F)RRVVRPC*GS >95
6 fRYAFWKIRYYKPSVCaK-fluorescein >95
7 fRYTTFTAVFLFRDRCGaK-fluorescein >95
8 fWTYYLIVSKSRNPHCaK-fluorescein 87
9 fKKTTIWRIRWTTRKCaK-fluorescein 80
10 FRSYSRRGRTWTYHCSK-fluorescein >95
[a] Small letters indicate non-natural amino acids: f=d-Phe; w=d-Trp;
a=b-alanine; (Me) stands for N-methylamino acids; bold C indicates the
location of the thioether bond to the N-terminal N-acetyl group. C* indi-
cates the use of S-acetaminomethyl (Acm) side-chain protection.
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larization in a competitive assay with a previously described
fluorescent probe.[63] None of the tested peptides induced ob-
servable changes in the polarization signal of the probe (re-
sults not shown). These results suggest that either they do not
bind to the protein interface with sufficient affinity to displace
the tracer or they bind to other regions of the protein. Alterna-
tively, fluorescent-labeled peptides (i.e. , peptides 6–10, Table 2)
were assayed directly with VEGF to assess their interaction abil-
ity. However, none of the peptides showed any significant
binding to VEGF.
Screening of fragment-based libraries
A fragment-based ligand discovery (FBLD) approach was se-
lected, because it provides a highly effective way of exploring
chemical space.[64–66] Fragment assembly allows access to very
large numbers of potential fragment combinations. Although
initial fragment hits are typically weak binders, two or more
fragments can be covalently linked to yield medium-sized
binders with higher affinity.
We used a chemical library that was designed by following
a rational selection procedure from a catalog of more than
1.2 million compounds from several international vendors (e.g. ,
Maybridge, Asinex and Enamine, Life Chemicals, Vitasmlab, and
Specs). The design workflow is shown in Figure 3. All com-
pounds in the library had commercial analogues to perform
what Hubbard and collaborators referred to as a “structure and
activity relationship (SAR) by catalog”.[67] This concept implies
that analogues from the original cluster can be ordered for
each active fragment, which thus generates SAR data in
a straightforward manner. A final library containing approxi-
mately 500 fragments, each one representing a large cluster,
was built.
To speed up the fragment screening, a previously described
computational approach[68] was used to group compounds
into cocktails that have minimized NMR signal overlap. This ap-
proach translates the NMR spectra of each compound into
a computer-readable format (fingerprint) and then minimizes
the global signal overlap by a SA (Monte–Carlo–Metropolis) al-
gorithm. Using this algorithm, 81 five-fragment mixtures, con-
taining a total of 402 compounds, were prepared. The frag-
ment mixtures showed an average signal overlap of only 2%.
Once assayed against VEGF by STD experiments, a group of
potential VEGF binders (27%) was selected from the initial li-
brary. Then, we explored whether they were interacting at the
expected site by using a competition STD experiment in the
presence of v107. However, no evidence of displacement by
v107 was observed for any of the fragments tested.
Alternatively, a reduced set of 100 compounds was tested in
a 19F NMR spectroscopy competition assay based on the dis-
placement of a fluorinated “spy molecule” from the binding
site of VEGF. For this purpose, a fluorinated v107-based pep-
tide was designed and synthesized (see the Supporting Infor-
mation). Two candidates seemed to partially compete with the
spy peptide in the 19F NMR spectroscopy assay. Unfortunately,
binding of these fragments to VEGF could not be validated by
protein-observed NMR spectroscopy techniques and they were
discarded.
19F NMR spectroscopy was also used to directly screen a pre-
viously described collection (FFCNIO library) of approximately
380 fluorinated compounds[69] against VEGF. They were group-
ed in eight-compound mixtures with non-overlapping 19F NMR
signals. We detected four low-affinity binders from the FFCNIO
library in the primary cocktail screening (see the Supporting In-
formation). However, none of these compounds behaved as an
efficient and selective VEGF binder if studied in isolation.
Several computational approaches, including molecular
docking and induced-fit docking calculations, were used to fur-
ther evaluate the fragment-based approach. The SiteMap
module of the Schrçdinger Suite[70] identified four potentially
druggable areas on the protein surface (i.e. , sites 1, 2, 3, and 4
in Figure 4a). Remarkably, the protein region involved in recep-
tor and v107 binding (i.e. , site 5, Figure 4a) was not among
the most “druggable” regions of VEGF. Next, by means of dock-
ing calculations by using XP Glide (Schrçdinger),[70] we exam-
ined the previously mentioned fragment-based library of ap-
proximately 500 compounds (Mr : 150–300 Da). XP Glide dock-
ing also confirmed the SiteMap results and showed better
binding options for sites 1 and 2 outside the receptor binding
site (Figure 4b). Finally, the search for potential transient sur-
face clefts by a protocol for induced-fit docking with Protein
Energy Landscape Exploration (PELE)[71] did not predict any
well-formed cleft in the receptor recognition region of VEGF.
Taken together, these in silico studies suggested that the most
probable binding regions of small fragments fall outside the
receptor binding site of VEGF.Figure 3. Overview of the strategy used for fragment selection.
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Natural compounds: flavonoids from medicinal plant
extracts as VEGF binders
A considerable number of drugs that are currently used in
cancer therapy are natural products or their derivatives.[72,73] In
this regard, traditional medicinal plants offer enormous poten-
tial in the search for new potential drugs. Cancer is among the
conditions treated by traditional herbal medicine. Interestingly,
some of the antitumoral plants or compounds used in tradi-
tional medicine operate through an antiangiogenic mecha-
nism, modulating one or various targets involved in vessel for-
mation. From the literature on traditional Chinese medicine,[74]
we selected a small subset of 50 plants for their high recur-
rence in medical prescriptions. Dried plant material was ex-
tracted with water by means of a Soxhlet apparatus. Given
that VEGF only contains five methionine residues, protein-de-
tected 13C-filtered-13C-decoupled 1H NMR spectroscopy was
used to detect potential VEGF binders. The spectra were ob-
tained with a one-dimensional version of the 1H–13C HSQC
pulse sequence, and they provided enough resolution to indi-
vidually resolve the resonances of the VEGF methionine resi-
dues in a time-efficient manner. Identical experiments were ac-
quired for free VEGF and for VEGF after the addition of mix-
tures of three different plant extracts. Two extract mixtures in-
duced spectral changes in VEGF. Next, individual extracts from
the positive mixtures were added to the protein. Small, yet
dose-dependent, minor shifts were observed for Met18 and
Met81 in the presence of extracts from Medulla Junci and
Radix scutellariae (Figure 5). In both cases, the shifts observed
were typical of weak binders in a fast exchange regime.
The chromatographic profiles of these extracts are shown in
Figure 5. We pursued the isolation and characterization of the
active compound(s) involved in VEGF binding. Using a combi-
nation of mass spectrometry and homonuclear (COSY and
NOESY) and heteronuclear (1H–13C HSQC and HMBC) NMR
spectroscopy techniques, the major component of the R. scu-
tellariae extract was identified as baicalin[75] (Figure 6). We then
confirmed that isolated baicalin was able to bind VEGF (Fig-
ures 5 and 6).
STD experiments were performed to identify the binding
epitope of baicalin (Figure 6). Relative quantification of trans-
ferred saturation indicated that the most buried part of the
molecule was the phenyl group, whereas the least saturated
and consequently the most exposed part was the more hydro-
philic glucuronic moiety. Finally, a STD competition assay with
peptide v107 was performed. Increasing amounts of v107 were
added to the baicalin–VEGF sample and subsequent STD ex-
periments were recorded. As shown in Figure 6, these experi-
ments revealed a stepwise reduction in the baicalin STD sig-
nals, which became undetectable in the presence of 100 mm
peptide v107, which thereby indicated that baicalin and v107
compete for the same binding site.
The interaction of baicalin with VEGF was further character-
ized by 1H–15N HSQC experiments. Upon the addition of baica-
lin, the most remarkable CSPs were found in a region centered
in residues 85–96. In addition, resonances corresponding to
amino acids in the vicinity of positions 46–48 and 18–22 were
also significantly shifted (Figure 7). Titrations were conducted
and baicalin-induced CSPs in the VEGF spectra were quantified
and used to determine the binding affinity; KD values of 4.9
and 6.8 mm were obtained for 1H–13C HSQC and 1H–15N HSQC
shifts, respectively (see the Supporting Information). Although
baicalin is a weak binder, it provides a reasonable starting
point to explore other structurally related, commercially avail-
able compounds.
A small set of several baicalin-related compounds were
chosen (Figure 7a). These molecules conserve the flavone scaf-
fold and show minor variations in the number and position of
several aromatic hydroxy groups. Of these molecules, the gly-
cosylated flavone quercetin-3-b-glucoside was the only one
that induced methionine perturbations on the 13C-filtered-13C-
decoupled 1H NMR spectra of VEGF. Titration of VEGF with this
glycosylated flavone provided a dissociation constant of
~2 mm, which suggests that quercetin-3-b-glucoside has
a slightly higher affinity than baicalin for VEGF (see the Sup-
porting Information). Comparison of the amide chemical shift
changes of VEGF induced by quercetin-3-b-gluocoside and bai-
calin revealed several interesting trends (Figure 7b). First, in
agreement with the differences in KD values estimated for the
two molecules, to produce similar chemical shift changes on
VEGF, the concentration of baicalin required was approximately
twice that required for quercetin-3-b-glucoside. Second, both
compounds affected a common cluster of amino acids cen-
tered on Phe47, in addition to some residues close to the N-
terminal a-helix 1, such as Met81 and Arg23. Beyond these
Figure 4. a) Analysis of the SiteMap computations reveals druggability
mainly in the channel formed between the two chains of the VEGF homodi-
mer (sites 1, 2, 3, and 4). Red, blue, and yellow surfaces show sites for poten-
tial H-bond acceptor, H-bond donor, and hydrophobic interactions, respec-
tively. White dots indicate the presence of small cavities. Receptor binding
sites are indicated by 5. The number size correlates with the size of the
binding sites. b) Representation of the XP GLIDE docking results. A selected
library of approximately 500 compounds (gray carbon atoms) was docked
against the VEGF homodimer (black ribbons). Sites 1 and 2 (panel a) were
most populated.
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similarities, most of the changes produced by baicalin were
concentrated around residues 86–93, located at b-strands 5
and 6 and their interconnecting loop. Conversely, quercetin-3-
b-glucoside-specific perturbations were mainly located on the
opposite site of VEGF, around Phe36 and the loop connecting
to the second b strand. These observations suggest that baica-
lin and quercetin-3-b-glucoside target overlapping but slightly
different sites on VEGF owing to their distinct binding orienta-
tions. Given that the two VEGF ligands share a common fla-
vone scaffold and differ mainly in the type and location of the
glycosidic moiety and to a lesser extent in the position of vari-
ous hydroxy groups, it is reasonable to place the common
scaffold on the locus of Phe47, the region equally affected by
these two flavonoid analogues. This model is in agreement
with the experimental STD data, which suggested that the
binding contribution of the flavone scaffold was stronger than
that of the glycosidic moiety. The glucuronic moiety of baicalin
is most likely accommodated between a-helix 1 and b-
strands 5 and 6, as residues in these secondary structure ele-
ments were selectively affected by baicalin. In contrast, the
sugar moiety of quercetin-3-b-glucoside is probably located on
the opposite site of the protein, which induces significant
shifts on Gly65 and residues on a-helix 2 (Figure 7c). Overall,
the screening of plant extracts from traditional Chinese medi-
cine allowed us to identify a flavonoid scaffold that is able to
bind VEGF in the VEGFR binding interface.
Discussion
The term “druggability” is used to describe a biological target
that is known to bind with high affinity to a low molecular
weight drug.[5] Many proteins, including several related to
cancer, are considered as “undruggable” targets.[76] The only
VEGF ligands that have found their way into clinical practice
are monoclonal antibodies[34–36] and, more recently, aptam-
ers.[38] In the present study, we summarized several years of
work of many members of our research group, and also of sev-
eral collaborators, in an effort to explore the feasibility of
a therapeutic strategy based on blocking the VEGFR interac-
tion by using ligands—other than biologics—able to bind
VEGF specifically in the region of interaction with its receptor.
Herein, we explored a wide variety of approaches, including
NMR spectroscopy based fragment screening, screening of
peptide libraries, and activity screening of plant extracts. This
extensive work provided a clear picture. First, it was difficult to
identify high-affinity ligands by using these approaches.
Second, the only ligands (weak) that bind to the VEGF surface
patch involved in the interaction with the receptor are confor-
mationally restrained cyclic peptides and medium-sized natural
products. Finally, all the small molecular weight organic frag-
ments able to bind VEGF interact with the protein in patches
other than the therapeutically relevant one.
This behavior, in particular the difficulties encountered to
identify small organic fragments targeting the VEGF interacting
surface, could be related to the topological and chemical fea-
Figure 5. Chromatographic profile of representative water extracts of a) Medulla Junci and c) Radix scutellariae. 13C-Filtered–13C decoupled 1H NMR spectra of
a 30 mm methyl-13C-Met-labeled VEGF sample in the absence (b and d, top) and in the presence of 3 mL (b and d, middle) and 6 mL (b and d, bottom) of
a stock solution, prepared as described in the Experimental Section, of either b) Medulla Junci or d) Radix scutellariae extracts.
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tures of the protein–protein interface. The VEGF–VEGFR-1 bind-
ing interface is flat, mainly hydrophobic, and rather large (>
800 2 per receptor unit),[13] which thereby suggests that tar-
geting this interaction may be especially challenging. However,
a compound interacting with the VEGF binding site in the
VEGFR D2 domain and inhibiting complex formation was re-
cently described.[39] This observation thus indicates that this
PPI may be amenable to disruption by synthetic compounds.
Several VEGF segments distant in sequence generate a discon-
tinuous binding epitope that contributes to receptor binding.
The binding determinants of VEGF for VEGFR are localized on
the N-terminal a-helix 1 (residues 16–27), the loop connecting
b3 to b4 (residues 61–66), and strand b7 (residues 103–106) of
one VEGF monomer as well as strand b2 (residues 46–48) and
strands b5 and b6, and the turn connecting them (residues
79–91).
Protein–protein interfaces could be structurally classified as
domain–domain or peptide–domain interactions.[4] In domain–
domain PPIs, two globular protein domains are involved in the
interface, whereas in peptide-mediated PPIs a continuous poly-
peptide segment binds to a globular domain. The size and
shape of the contact area differ considerably between the two
interaction types. Peptide-mediated interfaces have relatively
small contact areas with hot spot residues in close proximity.
In addition, members of this class tend to contain defined
pockets at the interface that may act as anchors of interacting
residues. These structural features make peptide-mediated in-
teractions more suited for inhibitors than the larger and flatter
domain–domain interfaces.
An increasing collection of PPI inhibitors has been de-
scribed.[8] Representative examples of successfully targeted PPI
interactions include, among others, those of the p53 activation
domain with MDM2,[77] Bcl-xL proteins with BH3 peptides,[78]
and cytokine interleukin-2 IL2 with its receptor IL2Ra.[79] More
recently, our research group reported a series of photoswitcha-
ble inhibitors of clathrin-mediated endocytosis able to disrupt
the b-arrestin–b-adaptin 2 interaction.[80,81] Most targeted PPIs
are either peptide–domain interactions or a fraction of
domain–domain PPIs that contain a continuous dominant pep-
tide at the interaction interface that contributes most of the
binding energy. In the latter case, inhibitors often target the in-
terface region in which the dominant peptide interacts.
The reasons why targeting VEGF has proven to be extremely
challenging are probably correlated with the absence of desira-
ble druggable features in VEGF. The VEGF–VEGFR interaction is
a typical domain–domain interaction. VEGF contains a relatively
flat and extended interface with hot spots distributed over
a large area. The distance between the Ca of Leu66 and Met18
is ~20 . Using several computational techniques, we predict-
ed the lack of preformed or transient cavities or clefts with po-
tential capacity to bind small molecules with reasonable affini-
ty in the receptor binding surface of VEGF.
The presence of large exposed hydrophobic surface patches
is one of the signatures of domain–domain PPIs. In this con-
text, our results suggest that to disrupt domain–domain PPIs li-
gands would need to expose hydrophobic surfaces that are
over a minimal threshold. This requirement translates, on the
one hand, into the need for a minimum molecular weight. On
the other hand, conformational constraints are required to pre-
vent these relatively large hydrophobic molecules to adopt en-
ergetically favored folded conformations that would shield the
hydrophobic functional groups from the water. In other words,
it would be necessary to force the hydrophobic parts of the
molecule to remain exposed at the surface, which would thus
facilitate interaction with the hydrophobic patch at the protein
surface. Our analysis could be applicable to other targets of
this nature and may help in the design of inhibitors and/or
screening strategies of many therapeutically relevant domain–
domain PPIs.
Experimental Section
Chemistry
Protein production : VEGF11109 (VEGF) was expressed, purified, and
refolded as described in detail elsewhere.[53] Large-scale expression
was performed on a 10 L scale with a Biostat B fermentor (Sartor-
ius). In this case, protein expression was induced once the culture
reached an optical density of 1.2 at 600 nm (OD600), and cells were
harvested at an OD600 of ~6.0. During the fermentation, oxygen
was supplemented into gas flow and the pH was kept constant at
7.0.
Peptide synthesis : A standard solid-phase Fmoc/tBu peptide syn-
thesis protocol was followed. Dipeptide libraries were supplied by
Figure 6. a) HPLC chromatogram of baicalin extracted from the Radix scutel-
lariae plant extract. The chemical structure of baicalin is shown (right).
b) STD NMR spectrum (T=298 K) of a sample containing 1 mm baicalin and
10 mm VEGF. STD spectra of the same sample in the presence of c) 50 mm
and d) 100 mm v107 peptide showing the reduction of the STD signal inten-
sities of baicalin in the presence of v107.
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Dr. F. Yraola from the Combinatorial Chemistry Unit at the Barcelo-
na Science Park. These libraries were produced by solid-phase syn-
thesis and were purified by HPLC to a purity 95% or higher. For
storage purposes, compounds were weighed and dissolved in
[D6]DMSO at a concentration of 100 mm.
For the synthesis of symmetric cyclic hexapeptide &d-Pro-Trp-Glu-
d-Pro-Trp-Glu&, 2-chlorotrityl resin (CTC resin, 250 mg,
1.6 mmolg1) was placed in a 20 mL polypropylene syringe fitted
with a polyethylene filter disc. The resin was then washed with
CH2Cl2 (530 s) and a solution of Fmoc-l-Trp(Boc)-OH (184.3 mg,
0.7 equiv) and N,N-diisopropylethylamine (DIEA; 366 mL, 10 equiv)
in CH2Cl2 was then added; the mixture was then stirred for 1 h at
room temperature. The remaining active sites were capped with
the addition of MeOH (400 mL), and the mixture was stirred for an
additional 10 min at room temperature. The Fmoc-l-Trp(Boc)-O-
CTC resin was subjected to the following washes: CH2Cl2 (530 s),
DMF (530 s), and 20% piperidine in DMF (11 min, 25 min, 1
10 min). Elongation of the peptide was achieved by the sequential
addition of Fmoc-AA-OH (3 equiv) with 2-(1H-7-azabenzotriazol-1-
yl)-1,1,3,3-tetramethyluronoium hexafluorphosphate (HATU,
3 equiv) and DIEA (6 equiv) as coupling reagents in DMF. The cou-
pling reaction was stirred for 30 min, and before filtration the cor-
responding colorimetric test (ninhydrin test for primary amines
and chloranil test for secondary amines) was done to qualitative
assess if coupling reactions were completed. Removal of the Fmoc
group was performed with 20% piperidine in DMF (11 min, 2
10 min, 110 min). The H-Glu(OtBu)-d-Pro-Trp(Boc)-Glu(OtBu)-d-
Pro-Trp(Boc)-O-CTC peptide resin was treated with 1% trifluoroace-
tic acid (TFA) in CH2Cl2 (530 s) to cleave the peptide from the
resin. The filtrates were collected over H2O (60 mL per gram of
resin). CH2Cl2 was removed under an atmosphere of nitrogen and
water was removed by lyophilization. The linear peptide was sub-
jected to head-to-tail cyclization in solution by using (7-azabenzo-
triazol-1-yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate
(PyAOP) and DIEA as coupling reagents in a mixture of CH2Cl2/DMF
(98:2) at high dilution (5 mm) for 16 h at room temperature. The
cyclic peptide was treated with TFA/H2O/triisopropylsilane (TIS)
(95:2.5:2.5, v/v/v) for 2 h at room temperature to remove all pro-
tecting groups. Solvent was removed under an atmosphere of ni-
Figure 7. a) Chemical structure of the flavonoid molecules tested. b) Histogram showing weighted average chemical shift changes for VEGF amide resonances
between free 15N-labeled VEGF (250 mm) and 15N-labeled VEGF (250 mm) in the presence of either 7.7 mm baicalin (black) or 4.4 mm quercetin-3-b-glucoside
(gray). c) Model of the VEGF–baicalin complex. VEGF is shown as a cartoon representation and baicalin as a ball and stick model.
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trogen, and the crude product was purified by CombiFlash auto-
mated flash chromatography (Teledyne ISCO) to obtain the final
peptide (39.1 mg, 47%). 1H NMR (600 MHz, H2O/D2O=90:10): d=
10.10 (s, 1H), 8.49 (d, J=7.6 Hz, 1H), 7.70 (d, J=8.1 Hz, 1H), 7.68
(d, J=8.8 Hz, 2H), 7.49 (d, J=8.5 Hz, 2H), 7.27 (s, 2H), 7.24 (t, J=
7.7 Hz, 2H), 7.16 (t, J=7.7 Hz, 2H), 4.26–4.17 (m, 1H), 3.71–3.62 (m,
1H), 3.62–3.54 (m, 1H), 3.48 (dd, J=15.6, 4.3 Hz, 1H), 3.22 (dd, J=
15.5, 9.5 Hz, 1H), 2.05–1.98 (m, 2H), 1.98–1.83 (m, 4H), 1.82–1.73
(m, 1H), 1.49–1.38 ppm (m, 1H). HPLC (solvent A: H2O with 0.045%
TFA, solvent B: MeCN with 0.036% TFA, conditions 7:3 to 0:10 in
15 min): tR=6.2 min. Purity: >98%.
mRNA display-derived peptides : Chloroacetylation of the free N
terminus was performed with a solution of 0.2m Cl-Ac-NHS (NHS=
N-hydroxysuccinimide; 2.5 mL) dissolved in N-methyl-2-pyrrolidone
(NMP) under shaking for 40 min. For fluorescein conjugation, after
chloroacetylation, the 4-methoxytrityl (Mmt) group was removed
by acidic solution (TFA/TIS/CH2Cl2, 1:1:98, v/v/v) for 10 min. The
peptidyl resin was then extensively washed with CH2Cl2 (31 min),
NMP (31 min), 10% DIEA in NMP (31 min), and NMP (31 min).
The peptidyl resin was subjected to a reaction with a solution of
0.1m NHS-fluorescein in 10% DIPEA in NMP for 1 h at room tem-
perature. Cleavage from the resin and removal of side-chain pro-
tecting groups was performed under stronger acidic conditions
(TFA/TIS/1,2-ethanedithiol (EDT)/H2O, 9.25:0.25:0.25:0.25, v/v/v/v)
for 3 h at room temperature. After removal of TFA, the crude prod-
uct was redissolved in DMSO (2.5 mL) and diluted with MeCN/H2O
(1:1, v/v, 1000 mL). The solution was adjusted to pH 9 with Et3N to
perform the head-to-side chain cyclization. The crude product was
purified by HPLC. Table 3 shows the characterization data from the
peptides obtained.
Plant extracts from traditional Chinese medicine : Plants were ob-
tained from Herbasin (Shenyang, China). Dried plant material (30 g)
was extracted with H2O (400 mL) at reflux for 5 h by means of
a Soxhlet apparatus. The volume of the aqueous extracts was re-
duced by evaporation under vacuum, and the extract was then
freeze dried. Finally, [D6]DMSO stocks were prepared at
a 200 mgmL1 concentration.
NMR spectroscopy
STD and WaterLOGSY experiments were conducted over a range of
temperatures (37, 25, or 5 8C) with Bruker Digital Avance 600 MHz
and Varian Inova 500 MHz spectrometers. Samples contained
10 mm VEGF and 0.5 or 1 mm of assayed compound(s) in 25 mm
sodium phosphate (pH 7.0), 50 mm NaCl, and 90% D2O. On-reso-
nance irradiation was performed on the water signal for WaterLOG-
SY experiments and on the aliphatic protein region for STD experi-
ments. The total saturation time was 2–2.5 s, and water suppres-
sion was achieved with a watergate module.
In the screening experiments, fragments showing STD signals with
“normal” or “strong” intensities for more than 30% of their protons
were classified as potential good binders.
Two-dimensional 1H–15N HSQC and 1H–13C HSQC experiments and
1D 13C-decoupled-13C-filtered 1H NMR spectra were usually ob-
tained at 45 8C with a Bruker Avance III 600 MHz spectrometer
equipped with a cryoprobe. Standard samples for protein-observed
experiments contained 100–200 mm (1H–15N HSQC) or 30 mm (1H–
13C HSQC and 1D 13C-decoupled-13C-filtered 1H) VEGF in buffer A:
25 mm sodium phosphate (pH 7.0), 50 mm NaCl, and 10% D2O. 2D
1H–13C HSQC experiments were typically acquired by using 256
96 points and 8 scans per increment with spectral widths of 960 Hz
(1.6 ppm) and 453 Hz (3.0 ppm) in the 1H and 13C dimensions, re-
spectively. Using this 13C spectral width, cross-signals of Met78
were folded. 13C-decoupled-13C-filtered 1H NMR spectra were re-
corded with 2048 points, a spectral width of 9000 Hz and
128 scans.
1H–15N HSQC spectra were acquired with 1024 complex points in
the F2 (1H) dimension and 100 increments in the F1 (15N) dimen-
sion, 96 scans for each increment, and a spectral width of 7212 Hz
(12.0 ppm) in F2 and 1794 Hz (29.5 ppm) in F1.
The dependence of the chemical shift changes of VEGF on the
ligand concentration was used to estimate binding constants.
1H NMR and 15N NMR chemical shift changes from 1H–15N HSQC ti-
trations or alternatively 1H NMR and 13C NMR shifts from 1H–13C
HSQC experiments were combined as previously described.[82] For
ligands interacting in the receptor-binding site of VEGF, two equal
and independent binding sites were assumed.[82]
All 19F NMR spectra were acquired with a Bruker spectrometer op-
erating at 700 MHz and equipped with a dual fluorine-proton SEF
probehead and a robotic arm BACS120. The CF3 and CF cocktail
samples for the 19F NMR screening were prepared at 20 and 50 mm,
respectively, by diluting premixed cocktail stocks (10 mm each of
the eight compounds in each stock) in [D6]DMSO in a final volume
of 550 mL of buffer A.
Two 19F NMR spectra for each cocktail sample were recorded: a reg-
ular 1D and a 1D containing a CPMG T2 filter of 200/400 ms (for
CF/CF3), before and after the addition of 2 mm VEGF. Spectra were
recorded with a 20 Hz sample spinning using 128 scans, acquisition
and recovery times of 1.2 s and 2.5 s, respectively, in 8.5–9.5 min
per spectrum.
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Table 3. Characterization of mRNA display-derived peptides.
Peptide HPLC[a] tR [min] Mass [m/z]
Expected Found
1 100:0–0:100 4.8 1109.43 (z=2) 1109.44 (z=2)
2 100:0–0:100 4.1 771.77 (z=3) 7771.77 (z=3)
3 100:0–30:70 4.9 796.40 (z=3) 796.40 (z=3)
4 95:5–0:100 4.1 465.40 (z=3) 765.40 (z=3)
5 90:10–50:50 4.4 722.05 (z=3) 722.05 (z=3)
6 80:20–50:50 7.7 908.44 (z=3) 908.44 (z=3)
7 100:0–0:100 4.9 899.42 (z=3) 899.42 (z=3)
8 80:20–50:50[b] 10 870.74 (z=3) 870.73 (z=3)
9 80:20–20:80 3.9 907.47 (z=3) 907.47 (z=3)
10 90:10–60:40 5.5 647.79 (z=4) 647.79 (z=4)
[a] HPLC gradient (8 min); solvent A: H2O + 0.045% TFA; solvent B: MeCN
+ 0.036% TFA [b] 15 min time gradient in a C4 column (4.6 mm15 mm).
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